Zobrazeno 1 - 10
of 653
pro vyhledávání: '"Endoxifen"'
Autor:
Debanjan Banerjee, Rajashree Ray
Publikováno v:
Consortium Psychiatricum, Vol 4, Iss 4, Pp 66-73 (2023)
Endoxifen, a protein kinase C inhibitor, has been approved for use in manic episodes in India. One of the symptom traits that it predominantly targets is impulsivity. Impulsivity can also be a symptom dimension of other mental health conditions, one
Externí odkaz:
https://doaj.org/article/10d12dc157a44f5cafa65d397a0e9f8a
Autor:
Oukseub Lee, Latifa A. Bazzi, Yanfei Xu, Erik Pearson, Minhua Wang, Omid Hosseini, Azza M. Akasha, Jennifer Nam Choi, Scott Karlan, Melissa Pilewskie, Masha Kocherginsky, Kelly Benante, Thomas Helland, Gunnar Mellgren, Eileen Dimond, Marjorie Perloff, Brandy M. Heckman-Stoddard, Seema A. Khan
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 171, Iss , Pp 116105- (2024)
Breast cancer prevention only requires local exposure of the breast to active drug. However, oral preventive agents entail systemic exposure, causing adverse effects that limit acceptance by high-risk women. Drug-delivery through the breast skin is a
Externí odkaz:
https://doaj.org/article/866b000bd0524b18baec1ef3a47518c6
Autor:
Sanne M. Buijs, Daan C.H. van Dorst, Marieke J.H.A. Kruip, Rob F.P. van den Akker, Ka L. Cheung, Robert Porrazzo, Esther Oomen-de Hoop, Agnes Jager, Stijn L.W. Koolen, Jorie Versmissen, A.H. Jan Danser, Henri H. Versteeg, Mettine H.A. Bos, Ron H.J. Mathijssen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 170, Iss , Pp 115969- (2024)
Background: Tamoxifen is an effective treatment for primary breast cancer but increases the risk for venous thromboembolism. Tamoxifen decreases anticoagulant proteins, including antithrombin (AT), protein C (PC) and tissue factor (TF) pathway inhibi
Externí odkaz:
https://doaj.org/article/36f8d4d8416b471296eb3d65386acbe7
Autor:
Oukseub Lee, Minhua Wang, Omid Hosseini, Maarten C. Bosland, Miguel Muzzio, Irene Helenowski, Seema A. Khan
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 162, Iss , Pp 114607- (2023)
Aggressive estrogen receptor (ER) positive breast cancer is frequently tamoxifen-resistant; alternative endocrine approaches exist for therapy, but not for prevention, particularly in premenopausal women. We examined the efficacy of the selective ER
Externí odkaz:
https://doaj.org/article/8344c8c8d0934f1d8bb111c6691ef418
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Amira Boucenna, Khadidja Boudaoud, Ahmed Hireche, Mohamed Larbi Rezgoune, Noureddine Abadi, Taha Filali, Dalila Satta
Publikováno v:
Egyptian Journal of Medical Human Genetics, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background Tamoxifen, a selective estrogen receptor modulator, is indicated for breast cancer developed in response to estrogen. Findings In the current study we explored the relationship between the different variants of CYP2D6, CYP2C19, CY
Externí odkaz:
https://doaj.org/article/a68d17d794f54cf3a4f07f9ddfc1ac8e
Autor:
Bram C. Agema, Sanne M. Buijs, Sebastiaan D.T. Sassen, Thomas E. Mürdter, Mathias Schwab, Birgit C.P. Koch, Agnes Jager, Ron H.N. van Schaik, Ron H.J. Mathijssen, Stijn L.W. Koolen
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 160, Iss , Pp 114369- (2023)
Background: Tamoxifen is important in the adjuvant treatment of breast cancer. A plasma concentration of the active metabolite endoxifen of > 16 nM is associated with a lower risk of breast cancer-recurrence. Since inter-individual variability is hig
Externí odkaz:
https://doaj.org/article/2396b06ab4c94959a7fe50d0e9284b90
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Thomas Helland, Bjørn Naume, Steinar Hustad, Ersilia Bifulco, Jan Terje Kvaløy, Anna Barbro Sætersdal, Marit Synnestvedt, Tone Hoel Lende, Bjørnar Gilje, Ingvil Mjaaland, Kjetil Weyde, Egil Støre Blix, Gro Wiedswang, Elin Borgen, Daniel Louis Hertz, Emiel Adrianus Maria Janssen, Gunnar Mellgren, Håvard Søiland
Publikováno v:
Molecular Oncology, Vol 15, Iss 4, Pp 957-967 (2021)
Low steady‐state levels of active tamoxifen metabolites have been associated with inferior treatment outcomes. In this retrospective analysis of 406 estrogen receptor‐positive breast cancer (BC) patients receiving adjuvant tamoxifen as initial tr
Externí odkaz:
https://doaj.org/article/162b341b32bb451fafcf55ad582ca776
Autor:
Clara Inkyung Lee, Siew Kee Low, Ricardo Maldonado, Peter Fox, Bavanthi Balakrishnar, Sally Coulter, Peter de Bruijn, Stijn L.W. Koolen, Bo Gao, Jodi Lynch, Nicholas Zdenkowski, Rina Hui, Christopher Liddle, Ron H.J. Mathijssen, Nicholas Wilcken, Mark Wong, Howard Gurney
Publikováno v:
Breast, Vol 54, Iss , Pp 229-234 (2020)
Introduction: CYP2D6 protein activity can be inferred from the ratio of N-desmethyl-tamoxifen (NDMT) to endoxifen (E). CYP2D6 polymorphisms are common and can affect CYP2D6 protein activity and E level. Some retrospective studies indicate that E 35;
Externí odkaz:
https://doaj.org/article/ee0a0636acad496f8fd6fecf0cdfe594